UroGen Pharma (URGN) director receives 20,000 stock options at $34.99 strike

Rhea-AI Filing Summary

UroGen Pharma Ltd. director Stuart Holden received a grant of stock options covering 20,000 ordinary shares. The options have an exercise price of $34.99 per share, expire on June 22, 2036, and vest in equal quarterly installments over one year, subject to his continuous service. Following this grant, he holds 20,000 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Holden Stuart

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right ot buy)	20,000	$0.00	--

Holdings After Transaction: Stock Option (right ot buy) — 20,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 20,000 options Exercise price: $34.99 per share Underlying shares: 20,000 ordinary shares +3 more

6 metrics

Stock options granted 20,000 options Grant to director on June 22, 2026

Exercise price $34.99 per share Strike price of granted options

Underlying shares 20,000 ordinary shares Shares covered by the options

Expiration date June 22, 2036 Option term end

Post-grant option holdings 20,000 options Total derivative holdings after award

Vesting schedule Quarterly over one year Subject to continuous service

Key Terms

Stock Option, Ordinary Shares, 2017 Equity Incentive Plan, Continuous Service

4 terms

Stock Option financial

"Stock Option (right ot buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

2017 Equity Incentive Plan financial

"as defined in the 2017 Equity Incentive Plan"

Continuous Service financial

"subject to the director's Continuous Service"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holden Stuart

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right ot buy)	$34.99	06/22/2026		A		20,000		(1)	06/22/2036	Ordinary Shares	20,000	$0	20,000	D

Explanation of Responses:

1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

	/s/ Jason D. Smith, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did UroGen Pharma (URGN) director Stuart Holden report in this Form 4?

Stuart Holden reported receiving a grant of stock options for 20,000 ordinary shares of UroGen Pharma. These options are compensation-related, not an open-market trade, and reflect an award tied to his role as a director.

How many UroGen Pharma (URGN) shares are covered by the new stock options?

The stock option grant covers 20,000 underlying ordinary shares of UroGen Pharma. This entire amount was reported in a single derivative transaction, with 20,000 options owned directly after the award.

What is the exercise price of Stuart Holden’s UroGen Pharma (URGN) options?

The options have an exercise price of $34.99 per share. This is the price at which he can buy UroGen Pharma ordinary shares if and when he exercises the stock options before they expire.

When do Stuart Holden’s UroGen Pharma (URGN) options expire?

The reported stock options expire on June 22, 2036. He can exercise them any time before that date, subject to vesting and the terms of UroGen Pharma’s 2017 Equity Incentive Plan.

How do the UroGen Pharma (URGN) options granted to Stuart Holden vest?

The options vest in equal quarterly installments over one year

Is Stuart Holden’s UroGen Pharma (URGN) Form 4 a buy or a grant?

The Form 4 reports a grant or award acquisition of stock options, not an open-market purchase. The transaction code is “A,” indicating a compensation-related award rather than a discretionary buy or sell in the market.